FWP

Forward Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.16
+0.17
+2.37%
Closed 16:00 02/21 EST
OPEN
7.23
PREV CLOSE
7.20
HIGH
7.30
LOW
6.85
VOLUME
21.15K
TURNOVER
--
52 WEEK HIGH
11.01
52 WEEK LOW
5.26
MARKET CAP
24.14M
P/E (TTM)
-0.1571
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FWP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FWP stock price target is 37.00 with a high estimate of 37.00 and a low estimate of 37.00.

EPS

FWP News

More
  • I, LJPC, MFGP and AEMD among midday movers
  • Seeking Alpha - Article · 02/04 17:39
  • Biogen Defends Its Blockbuster Against Mylan’s Patent Challenge
  • Barrons.com · 01/11 01:05
  • Did Hedge Funds Drop The Ball On Forward Pharma A/S (NASDAQ:FWP)?
  • Insider Monkey · 12/20/2019 22:13
  • CIEN, DBD, DPW and CEI among midday movers
  • Seeking Alpha - Article · 12/12/2019 17:41

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About FWP

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company's clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company's DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.
More

Webull offers kinds of Forward Pharma A/S stock information, including NASDAQ:FWP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWP stock news, and many more online research tools to help you make informed decisions.